39results about How to "Easy to reconstitute" patented technology

Described herein are nanoparticles which are largely made of (e.g., 90 wt. %) hydrophobic drugs and are stabilized by water soluble dyes. The nanoparticles can range in size from 30 nm to 150 nm and have highly negative surface charge (e.g., −55 mV). These nanoparticles are highly soluble in water, stable for days in PBS buffer and can be easily lyophilzed and reconstituted in water. Using quantitative self-assembly prediction calculations, topochemical molecular descriptors were identified and validated as highly predictive indicators of nano-assembly, nanoparticle size, and drug loading. The resulting nanoparticles selectively targeted kinase inhibitors to caveolin-1-expressing human colon cancer and autochthonous liver cancer models to yield striking therapeutic effects while avoiding pERK inhibition in healthy skin. The nanoparticles exhibited remarkable anti-tumor efficacy in vitro and in vivo in models of hepatocellular carcinoma.

The invention relates to an officinal composition of vidarabine monophosphate for injection, wherein the main active components of the composition comprise vidarabine monophosphate and lysine.

The invention belongs to the technical field of medicines, and particularly relates to palonosetron hydrochloride freeze-dried powder injection. The invention also relates to preparation of the freeze-dried powder injection. By adding beta-cyclodextrin or hydroxypropyl beta-cyclodextrin and mannitol, the palonosetron preparation has the characteristics of being smooth in surface, delicate, uniform, free of cracks, breakage and adhesion to a bottle, white in color, shaped like a loose piece, good in formation, also good in dissolubility, quite easy to dissolve, clear and transparent in solution and stable in product quality.

The object of the invention is to provide an immunological reconstitution promoter or a prophylactic agent for infections for use in allogeneic hematopoietic stem cell transplantation therapy for tumors. The promoter or prophylactic agent enables the amelioration of delayed immune reconstitution or the prevention of infection following transplantation, while maintaining the GVT effect of allogeneic hematopoietic stem cell transplantation. Specifically, in a transplant patient in whom immune reconstitution is delayed, such reconstitution can be promoted by administering, at an early stage following transplantation, a substance capable of depleting CD4⁺ cells. Early completion of infection management in the patient and improvement in the survival rate are anticipated as a result. In addition, the risk of complications associated with allogeneic hematopoietic stem cell transplantation is reduced, enabling more widespread use of this therapy.

The invention discloses a micro-balloon injection for a pharmaceutical composition of cefmenoxime hydrochloride / anhydrous sodium carbonate, which is characterized by comprising cefmenoxime hydrochloride, anhydrous sodium carbonate, polylactic acid- polyethylene glycol block copolymer, poloxamer 188, glycerol and mannitol. The optimal scheme of the invention is the micro-balloon injection for the pharmaceutical composition of cefmenoxime hydrochloride / anhydrous sodium carbonate, which is characterized by comprising 1 part of cefmenoxime hydrochloride, 0.12-0.18 part of anhydrous sodium carbonate, 1.2-4.5 parts of polylactic acid- polyethylene glycol block copolymer, 0.8-2 part(s) of poloxamer 188, 0.5-1 part of glycerol and 3-6 parts of mannitol. Compared with the prior art, the micro-balloon injection for the pharmaceutical composition of cefmenoxime hydrochloride / anhydrous sodium carbonate prepared by the invention has high stability, the preparation process is simple and is suitable for industrial production, and has high encapsulation efficiency. As anhydrous sodium carbonate is used as a latent solvent, the re-dissolution is good, and has an appropriate slow-release effect.

The invention discloses a preparation method of urchin-like nano gold particles. The preparation method is characterized by mainly comprising the following steps: adding a chloroauric acid solution into an N-(2-ethoxy) piperazine-N'-2-ethanesulfonic acid solution, carrying out full and uniform stirring and mixing, slowly stirring the solution till the solution turns from colorless transparency into a dark blue color, stopping stirring, stewing for 10 to 25 minutes to fully complete the reaction, and then adding citric acid or potassium carbonate to adjust the pH value to be 5.5 to 8.5. Compared with the prior art, the preparation method has the advantages of quickness, no need of gold seeds, green synthesis and the like.

The medical diagnosis reagent powder re-dissolving device includes a liquid container, a powder container and a connection structure for mixing liquid or dissolving powder. The corresponding re-dissolving is also disclosed. The present invention can realize the inflow of liquid to the powder, the entering of powder into the liquid or the inflow of one kind of liquid to the other for mixing without need of opening the powder bottle lid and liquid bottle lid successively or simultaneously. The present invention can facilitate the measurement in spectrophotometer, semi-automatic biochemical analyzer and automatic biochemical analyzer, and has convenient operation, high efficiency, and high reagent stability.

The invention discloses a microsphere injection of a medicinal composition of cefotiam hydrochloride and anhydrous sodium carbonate, which is characterized by consisting of the cefotiam hydrochloride, the anhydrous sodium carbonate, PLGA, fatty acid sorbitan-80, glycerol and sorbitol, in particular 1 part of the cefotiam hydrochloride, 0.15 to 0.2 part of the anhydrous sodium carbonate, 2.5 to 5 parts of PLGA, 1 to 3 parts of the fatty acid sorbitan-80, 0.8 to 1.5 parts of the glycerol and 5 to 10 parts of the sorbitol. Compared with the prior art, the microsphere injection of the medicinal composition of the cefotiam hydrochloride and the anhydrous sodium carbonate has the characteristics of high stability, high encapsulation rate and suitable slow-releasing effect, and a preparation process of the microsphere injection is suitable for industrial production.

The invention discloses cefamandole nafate/anhydrous sodium carbonate medicinal composition microsphere injection, which is characterized by consisting of cefamandole nafate, anhydrous sodium carbonate, PGLA, Tween-80, propylene glycol and glucose. The invention adopts the preferable scheme that the cefamandole nafate/anhydrous sodium carbonate medicinal composition microsphere injection is characterized by comprising the following components in part by weight: 1 part of cefamandole nafate, 0.08 to 0.12 part of anhydrous sodium carbonate, 1.5 to 6 parts of PGLA, 0.2 to 2 parts of Tween-80, 0.3 to 3 parts of propylene glycol and 2 to 8 parts of glucose. Compared with the prior art, the prepared cefamandole nafate microspheres have stability, a preparation process is simple and suitable for industrialized production, the entrapment rate is high, and the anhydrous sodium carbonate used as a co-solvent has good resolution and proper slow-release effect.

The invention discloses a flucloxacilin sodium liposome injection. The flucloxacilin sodium liposome injection is mainly prepared from flucloxacilin sodium, polysorbate 80, gylcocholic acid sodium salt, gelatin, glycerol and sodium chloride; the defect of instability of the flucloxacilin preparation is overcome; and the liposome injection is prepared by protecting flucloxacilin sodium package by using liposome and then performing spray drying and aseptic subpackage, so that the stability of the flucloxacilin sodium is greatly increased, the preparation process is simple, yield is high, and solubility is high. The product quality of the preparation is improved and the toxic and side effects are reduced.

The invention relates to the technical field of freeze-drying of biological reagents, in particular to aFreeze-dried preparation production process. A pipettor tip is used as a carrier of the Freeze-dried preparation. The pipettor suction head sucks the stock solution and then directly carries out cryopreservation in the pipettor suction head to generate a freeze-dried reagent, and then packagingis carried out. When in use, the pipette is directly connected. The invention also discloses aFreeze-dried reagent preparation box based on the pipettor sucker as a carrier of a lyophilized preparation. The Freeze-dried reagent preparation box comprises a shell, the pipettor sucker and a reconstitution fluid carrier. The shell is provided with a cavity with an open upper part; a freeze-dried reagent is placed at the bottom of the pipettor sucker; the reconstitution fluid carrier is provided with a liquid tank, a liquid tank film is arranged at the upper part of the liquid tank, and a reconstitution fluid is stored in the reconstitution fluid carrier; the pipettor sucker is positioned at the upper part of the reconstitution fluid carrier, and the tip faces the liquid tank film; and a sealing piece is arranged at the upper opening of the cavity of the shell. The invention is convenient for storage and transportation of freeze-dried reagents, is convenient for redissolving of the freeze-dried reagents, and avoids pollution in the redissolving process.

The invention discloses a clinical biochemical composite quality control product which comprises a detection item raw material, a matrix liquid and a protective agent, a detection item comprises the following raw materials: alkaline phosphatase, amylase, sodium glycochenodeoxycholate, cholinesterase, creatinine, leucine aminopeptidase, lactic dehydrogenase, lipase, triglyceride, cholesterol, uric acid, urea, alanine aminotransferase, asparaginic acid aminotransferase, gamma-glutamyl transferase, glucose, alpha-hydroxybutyrate dehydrogenase and sodium hydrogen phosphate. Magnesium chloride, calcium chloride, ferrous chloride, bilirubin, amylopsin and sodium bicarbonate; the matrix liquid is bovine serum albumin and human serum albumin; the protective agent comprises dithiothreitol (DTT), mannitol, trehalose, sodium chloride, a compound enzyme stabilizer AES and sodium azide. The quality control product disclosed by the invention can realize detection of 27 clinical biochemical items, and the freeze-drying process is adopted, so that the obtained freeze-dried composite quality control product is low in viscosity, easy to redissolve and uniformly mix, strong in stability and relatively small in matrix effect.